Neovascular AMD Dosing Regimens and Impact of Residual Retinal Fluid: A Wheel of Knowledge Challenge!

Author(s)/Faculty: Michael S. Ip, MD; Rishi P. Singh, MD
Release Date: 12/23/2021Expiration Date: 12/22/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.5
Content Type: GamingProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, and offers many patients delayed or arrested disease progression and the possibility of regaining lost vision. The discovery that intravitreal therapy can be effective in treating neovascular age-related macular degeneration (nAMD) has spurred further research exploring the outcomes of treatment regimens using this approach. Further, newer protocols that allow for longer intervals between treatment are now available and hold promise in lessening treatment burden. Yet, ophthalmologists are challenged to select the most appropriate dosing regimen and are unsure of the effect of residual retinal fluid following treatment. In this gaming activity, expert faculty will assess anti-VEGF dosing and administration regimens in the treatment of nAMD, evaluate the efficacy of anti-VEGF therapy in the long-term management of patients with nAMD, and evaluate clinical evidence regarding residual retinal fluid and how it may impact visual outcomes in patients with nAMD.